Development of Bacteriophage Therapy for Antimicrobial-Resistant Infections in Cystic Fibrosis - Paul Bollyky, MD, PhD

Dr. Paul Bollyky, an Associate Professor and an infectious disease physician at Stanford University, presents results from CFRI-funded research on the development of phage therapy for antimicrobial-resistant infections in CF. He discusses a novel approach to design effective, broad-spectrum phage cocktails that relies on combining phages with different, complimentary receptors. This presentation was part of CFRI's 36th National CF Education Conference.

CFRI's 36th National CF Education Conference was sponsored by Viatris, Vertex Pharmaceuticals, Gilead Sciences, Chiesi USA, AbbVie, Genentech, and the Boomer Esiason Foundation.